307 related articles for article (PubMed ID: 22333271)
1. Identification of common genetic modifiers of neurodegenerative diseases from an integrative analysis of diverse genetic screens in model organisms.
Chen X; Burgoyne RD
BMC Genomics; 2012 Feb; 13():71. PubMed ID: 22333271
[TBL] [Abstract][Full Text] [Related]
2. Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms.
van Ham TJ; Breitling R; Swertz MA; Nollen EA
EMBO Mol Med; 2009 Nov; 1(8-9):360-70. PubMed ID: 20049741
[TBL] [Abstract][Full Text] [Related]
3. Regulation of protein homeostasis in neurodegenerative diseases: the role of coding and non-coding genes.
Sin O; Nollen EA
Cell Mol Life Sci; 2015 Nov; 72(21):4027-47. PubMed ID: 26190021
[TBL] [Abstract][Full Text] [Related]
4. Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.
Costa MD; Maciel P
Cell Mol Life Sci; 2022 May; 79(5):274. PubMed ID: 35503478
[TBL] [Abstract][Full Text] [Related]
5. Functional genomics approaches to neurodegenerative diseases.
Rubinsztein DC
Mamm Genome; 2008 Sep; 19(9):587-90. PubMed ID: 18665420
[TBL] [Abstract][Full Text] [Related]
6. Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale.
Ruffini N; Klingenberg S; Schweiger S; Gerber S
Cells; 2020 Dec; 9(12):. PubMed ID: 33302607
[TBL] [Abstract][Full Text] [Related]
7. Neurodegenerative conditions associated with ageing: a molecular interplay?
Troulinaki K; Tavernarakis N
Mech Ageing Dev; 2005 Jan; 126(1):23-33. PubMed ID: 15610759
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in neurodegenerative diseases and its accessibility in the model organism Caenorhabditis elegans.
Wang YA; Kammenga JE; Harvey SC
Hum Genomics; 2017 May; 11(1):12. PubMed ID: 28545550
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetics approaches in yeast to study amyloid diseases.
Outeiro TF; Muchowski PJ
J Mol Neurosci; 2004; 23(1-2):49-60. PubMed ID: 15126692
[TBL] [Abstract][Full Text] [Related]
10. Neurodegenerative disorders: insights from the nematode Caenorhabditis elegans.
Dimitriadi M; Hart AC
Neurobiol Dis; 2010 Oct; 40(1):4-11. PubMed ID: 20493260
[TBL] [Abstract][Full Text] [Related]
11. C. elegans as a Model for Synucleinopathies and Other Neurodegenerative Diseases: Tools and Techniques.
Koopman M; Seinstra RI; Nollen EAA
Methods Mol Biol; 2019; 1948():93-112. PubMed ID: 30771173
[TBL] [Abstract][Full Text] [Related]
12. Natural Genetic Variation in Yeast Reveals That NEDD4 Is a Conserved Modifier of Mutant Polyglutamine Aggregation.
Peters TW; Nelson CS; Gerencser AA; Dumas KJ; Tavshanjian B; Chang KC; Lithgow GJ; Hughes RE
G3 (Bethesda); 2018 Nov; 8(11):3421-3431. PubMed ID: 30194090
[TBL] [Abstract][Full Text] [Related]
13. The contribution of
Liang JJH; McKinnon IA; Rankin CH
J Neurogenet; 2020; 34(3-4):527-548. PubMed ID: 32772603
[TBL] [Abstract][Full Text] [Related]
14. Modeling neurodegenerative diseases in Caenorhabditis elegans.
Li J; Le W
Exp Neurol; 2013 Dec; 250():94-103. PubMed ID: 24095843
[TBL] [Abstract][Full Text] [Related]
15. Using Drosophila melanogaster to uncover human disease gene function and potential drug target proteins.
Reiter LT; Bier E
Expert Opin Ther Targets; 2002 Jun; 6(3):387-99. PubMed ID: 12223075
[TBL] [Abstract][Full Text] [Related]
16. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
Nagai Y; Popiel HA
Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
[TBL] [Abstract][Full Text] [Related]
17. Modeling polyglutamine pathogenesis in C. elegans.
Brignull HR; Morley JF; Garcia SM; Morimoto RI
Methods Enzymol; 2006; 412():256-82. PubMed ID: 17046663
[TBL] [Abstract][Full Text] [Related]
18. RACK1 modulates polyglutamine-induced neurodegeneration by promoting ERK degradation in Drosophila.
Xie J; Han Y; Wang T
PLoS Genet; 2021 May; 17(5):e1009558. PubMed ID: 33983927
[TBL] [Abstract][Full Text] [Related]
19. Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
Kumar P; Pradhan K; Karunya R; Ambasta RK; Querfurth HW
J Neurochem; 2012 Feb; 120(3):350-70. PubMed ID: 22098618
[TBL] [Abstract][Full Text] [Related]
20. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
